Trials / Active Not Recruiting
Active Not RecruitingNCT05612568
5 Years of Eye Screening for ARF in Children Aged <3 Years in Flanders
Five Years of Eye Screening for Amblyopia Risk Factors in Children Aged <3 Years in Flanders: Epidemiological Retrospective Study
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 250,000 (estimated)
- Sponsor
- Universitaire Ziekenhuizen KU Leuven · Academic / Other
- Sex
- All
- Age
- 13 Months – 31 Months
- Healthy volunteers
- Accepted
Summary
Researchers will investigate the distribution and evolution of amblyopia risk factors and other refractive errors in children younger than 3 years of age. The significance and magnitude of current global evolutions in ARF and refractive errors will be verified to update current guidelines and practices. Better insight in associated factors of amblyopia risk factors will contribute to current understanding of amblyopia.
Detailed description
The eye screening program of the Flemish governmental agency 'Kind en Gezin' is a well-implemented screening program for detection of ARF in children under the age of 3 years. This screening covers almost 85% of all children born in the Flemish community. Valuable information about distribution and determinants of refractive errors and ARF are collected at 'Kind en Gezin', but remain unstudied until today. The aim is to analyze the distribution and evolution of refractive errors in children under the age of 3 years in Flanders. One supposes that identification of patterns in this distribution, and identification of determinants that influence ARF, will lead to improved knowledge about amblyopia (risk factors) and on their turn help optimize the ARF screening program. Evaluation of the distribution and evolution of refractive errors over time, and comparison with global results, will also give researchers insight in the significance of the myopia epidemic in Flanders.
Conditions
Timeline
- Start date
- 2022-09-01
- Primary completion
- 2025-06-01
- Completion
- 2025-09-01
- First posted
- 2022-11-10
- Last updated
- 2024-07-01
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT05612568. Inclusion in this directory is not an endorsement.